MLTX vs MNOV

MoonLake Immunotherapeutics vs MediciNova, Inc. — Valuation Comparison 2026

MLTX

Biotechnology
MoonLake Immunotherapeutics
Quality
4.0
out of 10
Value Trap
30
LOW
Price
$18.68
Last close
Models
7/13
Active
VS

MNOV

Biotechnology
MediciNova, Inc.
Quality
6.2
out of 10
Value Trap
45
WARN
Price
$1.37
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType MLTX Fair ValueMLTX Upside MNOV Fair ValueMNOV Upside
Bayesian DCF Intrinsic $6.65 -64.4% $0.67 -51.1%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.45 -97.3% $0.04 -97.1%
Dynamic NAV Asset-Based $4.61 -75.3% $1.33 -3.2%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for MLTX vs MNOV — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MLTX vs MNOV — Which Stock Is More Undervalued?

MNOV scores higher with a 6.2/10 quality rating vs MLTX's 4.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing MoonLake Immunotherapeutics (MLTX) and MediciNova, Inc. (MNOV) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MLTX currently trades at $18.68 with a QOC of 4.0/10, while MNOV trades at $1.37 with a QOC of 6.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).